Radical treatment not the only way, NICE stresses in prostate guideline
This article was originally published in Clinica
The UK Prostate Brachytherapy Advisory Group (PBAG) says that a new guideline on best practice for the diagnosis and treatment of prostate cancer represents a step forward for patient choice. The guideline, issued in late February by the National Institute for Health and Clinical Excellence (NICE), covers the tests, treatment, care and support that men who have suspected or diagnosed prostate cancer should be offered (not care for rare cancers). NICE clinical and public health director Professor
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.